Document:

Exhibit 10.20

Summary
of Director Compensation

                We provide cash compensation and stock options to
non-employee members of our board of directors for serving on our board of
directors.  After the closing of this
offering, we will pay each of our non-employee directors $25,000 per year for
serving on our board of directors.  In
addition to compensation for board services, we will pay the members of our
committees $10,000 per year to each member of our audit committee and $5,000
per year to each member of our compensation committee and governance and
nominating committee.  In addition to any
payments for being a member of the various committees of our board of
directors, we will also pay the chair of the audit committee $10,000 and the
chairs of each of the compensation committee and the governance and nominating
committee $5,000.  We also pay each
member of the board of directors $1,500 per meeting of the board of
directors.  Members of our board of
directors are reimbursed for some expenses in connection with attendance of
board and committee meetings.

                Each of our directors, on the date the director is
first elected or appointed to the board of directors, will automatically be
granted an option to acquire 15,000 shares of common stock on the date of the
grant.  The initial grant will vest
quarterly over three years.  In addition,
upon election of directors each year, each director will receive an automatic
grant of options to acquire 5,000 shares of common stock on a fully diluted
basis on the date of the grant.  These
options will also vest quarterly over three years.Exhibit 10.21

 

 

MONOSOL RX, LLC

AMENDED AND RESTATED

PERFORMANCE UNITS PLAN

 

Amended
and Restated Effective September 18, 2006

 

 

 

 

 

 

TABLE OF
CONTENTS

 

	
   

  	
   

  	
  Page

  
	
   

  	
   

  	
   

  
	
  ARTICLE I

  	
  DEFINITIONS

  	
  1

  
	
   

  	
   

  	
   

  
	
  ARTICLE II

  	
  ADMINISTRATION

  	
  3

  
	
   

  	
   

  	
   

  
	
  2.01

  	
  Advisory Board; Duties

  	
  3

  
	
  2.02

  	
  Agents

  	
  3

  
	
  2.03

  	
  Binding Effect of
  Decisions

  	
  3

  
	
  2.04

  	
  Indemnity of Advisory
  Board

  	
  3

  
	
   

  	
   

  	
   

  
	
  ARTICLE III

  	
  PARTICIPATION

  	
  3

  
	
   

  	
   

  	
   

  
	
  3.01

  	
  Participation

  	
  3

  
	
  3.02

  	
  Performance Units

  	
  4

  
	
  3.03

  	
  Vesting of Performance
  Units

  	
  4

  
	
  3.04

  	
  Dilution and Other
  Adjustments

  	
  4

  
	
   

  	
   

  	
   

  
	
  ARTICLE IV

  	
  BENEFITS

  	
  5

  
	
   

  	
   

  	
   

  
	
  4.01

  	
  Benefit Payments
  Following Change in Control

  	
  5

  
	
  4.02

  	
  Forfeiture Provisions

  	
  5

  
	
  4.03

  	
  Withholding; Payroll
  Taxes

  	
  6

  
	
   

  	
   

  	
   

  
	
  ARTICLE V

  	
  BENEFICIARY DESIGNATION

  	
  6

  
	
   

  	
   

  	
   

  
	
  5.01

  	
  Beneficiary Designation

  	
  6

  
	
  5.02

  	
  Amendments

  	
  6

  
	
   

  	
   

  	
   

  
	
  ARTICLE VI

  	
  AMENDMENT AND
  TERMINATION

  	
  6

  
	
   

  	
   

  	
   

  
	
  6.01

  	
  Right to Amend

  	
  6

  
	
  6.02

  	
  Termination

  	
  6

  
	
   

  	
   

  	
   

  
	
  ARTICLE VII

  	
  CLAIMS PROCEDURE AND
  DISPUTES

  	
  7

  
	
   

  	
   

  	
   

  
	
  7.01

  	
  Claim Filing Procedure

  	
  7

  
	
  7.02

  	
  Consideration of Claim;
  Rendering of Decision

  	
  7

  
	
  7.03

  	
  Limitation on Claims
  Procedure

  	
  7

  
	
  7.04

  	
  Dispute over Benefits

  	
  7

  
	
   

  	
   

  	
   

  
	
  ARTICLE VIII

  	
  MISCELLANEOUS

  	
  8

  
	
   

  	
   

  	
   

  
	
  8.01

  	
  Headings and Gender

  	
  8

  
	
  8.02

  	
  No Right to Employment
  or Retention

  	
  8

  
	
  8.03

  	
  Action by Officers

  	
  8

  

 

i

 

	
  8.04

  	
  Assignment of Benefits

  	
  8

  
	
  8.05

  	
  Applicable Law;
  Validity

  	
  8

  
	
  8.06

  	
  Expenses

  	
  9

  
	
  8.07

  	
  Plan Funding

  	
  9

  

 

ii

 

MONOSOL RX, LLC

AMENDED AND RESTATED

PERFORMANCE UNITS PLAN

 

Amended and Restated Effective
September 18, 2006

 

MONOSOL RX, LLC, a
Delaware limited liability company (the “Company”), does hereby amend and
restate the Performance Units Plan (hereinafter referred to as the “Plan”).  The Plan was established by the Company,
effective as of January 22, 2004, for the purpose of enhancing the long-term growth
in earnings of the Company by providing incentives to key employees and/or
other service providers of the Company. 
The Plan helps the Company attract and retain employees and other
service providers of exceptional ability.

 

ARTICLE I

DEFINITIONS

For the purposes of this Plan, the following words and phrases shall
have the meanings indicated, unless the context clearly indicates otherwise:

 

“Additional Performance Units Plan” shall mean the other Performance
Units Plan B established by the Company effective as of January 22, 2004.

 

“Advisory Board” shall mean the Advisory Board contemplated by the
Company Agreement which administers the Plan pursuant to Article II.

 

“Base Value” shall mean $12,500,000.00, the Base Value determined by
the Advisory Board on January 22, 2004.

 

“Beneficiary” shall mean the person, persons or entity designated by
the Participant, as provided in Article V, to receive any benefits payable
under the Plan following the death of the Participant.

 

“Cause” shall mean the involuntary termination of a Participant’s employment
or other service-providing relationship with the Company resulting from (i)
willful, reckless or negligent conduct by such Participant in connection with
his employment with, or provision of services to, the Company, (ii) the
conviction of such Participant of any felony or any crime involving moral
turpitude, (iii) such Participant’s reporting to work or performing services impaired
by or under the influence of alcohol or illegal drugs, (iv) such Participant’s
engaging in the unlawful use (including being under the influence) or
possession of illegal drugs on the Company’s premises, (v) such Participant’s
engaging in sexual harassment or otherwise violated any harassment or
discrimination law, or (vi) dishonesty of such Participant.

 

“Change in Control” shall mean the occurrence, after the effective date
of the Plan, in a single transaction or series of transactions, of any one of
the following events or circumstances: (i) merger, consolidation or
reorganization of the Company where the beneficial owners of the

 

 

interests or securities possessing the right to vote
with respect to the Company immediately preceding the merger, consolidation or
reorganization beneficially own less than 20% of the interests or securities
possessing the right to vote with respect to the survivor entity, after giving
effect to such merger, consolidation, or reorganization; (ii) acquisition by
any person or group, as defined for purposes of Section 13(d)(3) of the
Securities Exchange Act of 1934, as amended, of beneficial ownership of
interests or securities possessing the right to vote with respect to the
Company where the beneficial owners of the interests or securities possessing
the right to vote with respect to the Company immediately preceding such
acquisition own less than 20% of the interests or securities possessing the
right to vote with respect to the Company, after giving effect to such
acquisition; (iii) approval by the members of the Company of a plan of
liquidation or dissolution with respect to the Company, provided such
liquidation or dissolution is consummated; (iv) the sale, exchange, or
contribution of all or substantially all the Company’s assets to an entity
where the beneficial owners of the interests or securities possessing the right
to vote with respect to the Company immediately preceding the sale, exchange,
or contribution beneficially own less than 20% of the interests or securities
possessing the right to vote with respect to the acquiring entity; or (v) an
initial public offering under the Securities Act of 1933, as amended, of the
business of the Company to the public which does not otherwise meet the
definition of a Change in Control in clause (i) — (iv) hereof.  In the event the exact date of a Change in
Control cannot be determined, such Change in Control will be deemed to have
occurred on the earliest date on which it could have occurred.

 

“Claim” shall mean a request by a Claimant in accordance with Article
VII for a benefit under the Plan.

 

“Claimant” shall mean any Participant or Beneficiary who claims to be
entitled to a benefit under the Plan.

 

“Code” shall mean the Internal Revenue Code of 1986, as amended from
time to time (or any corresponding provisions of succeeding law).

 

“Company” shall mean Monosol RX, LLC, a Delaware limited liability
company, and any successor to the business thereof.

 

“Company Agreement” shall mean the Limited Liability Operating
Agreement of the Company, as amended from time to time.

 

“Market Value”, at any point in time, shall mean the fair market value
of the Company’s business as of such time. 
The fair market value of the Company’s business shall be the price a
willing buyer would pay to purchase the Company’s entire business, subject to
existing liabilities, in a lump sum, cash payment.  In the case of an actual sale of the Company’s
business or other transaction resulting in a Change in Control, the sale price
or value of consideration given shall be determinative of the fair market value
of the Company’s business.

 

“Outstanding Unit Amount” at any point in time (and subject to
adjustment under Section 3.04) shall mean (i) the maximum number of Performance
Units that may be granted under the Plan as of such time, plus (ii) the number
of Performance Units that, solely for purposes of the

 

2

 

Plan, represents the maximum number of Performance
Units that may be granted under the Additional Performance Units Plan, plus (iii)
the number of Performance Units that, solely for purposes of the Plan,
represents the total outstanding member interests of members of the Company as
of such time (as determined by the Advisory Board).  Based upon adjustments under Section 3.04
since the establishment of the Plan on January 22, 2004, the Outstanding Unit
Amount as of September 18, 2006, shall be 100,000,000.

 

“Participant” shall mean an individual who
is eligible to participate in the Plan as provided in Article III.

 

“Performance Units” shall mean contractual rights awarded to a
Participant as provided in Article III.

 

“Vested” shall mean the extent to which a Participant has earned a
right to receive benefit payments with respect to his Performance Units
pursuant to Section 3.03, subject to the forfeiture provisions of Section 4.02.

 

ARTICLE II

ADMINISTRATION

 

2.01         Advisory
Board; Duties.  The Plan shall be
administered by the Advisory Board. 
Members of the Advisory Board may be Participants under the Plan.  The Advisory Board shall also have the
authority to make, amend, interpret, and enforce all appropriate rules and
regulations for the administration of the Plan and decide or resolve any and
all questions, including interpretations of the Plan, as may arise in
connection with the Plan.

 

2.02         Agents.  In the administration of the Plan, the Advisory
Board may, from time to time, employ agents and delegate to them such
administrative duties as it sees fit and may from time to time consult with
legal counsel who may also be legal counsel to the Company.

 

2.03         Binding
Effect of Decisions.  The decision or
action of the Advisory Board in respect of any question arising out of or in
connection with the administration, interpretation and application of the Plan
and the rules and regulations promulgated hereunder shall be final and
conclusive and binding upon all persons having any interest in the Plan.

 

2.04         Indemnity
of Advisory Board.  The Company shall
indemnify and hold harmless the members of the Advisory Board against any and
all claims, loss, damage, expense or liability arising from any action or
failure to act with respect to the Plan, except in the case of gross negligence
or willful misconduct by the Advisory Board.

 

ARTICLE III

PARTICIPATION

 

3

 

3.01         Participation.  Participation in the Plan shall be limited to
the following individuals: Richard C. Fuisz, Joe Fuisz, Garry Myers and Robert
Yang.

 

3.02         Performance
Units.  On January 22, 2004, Performance
Units were granted under this Plan to the Participants as follows:

 

	
  Individual

  	
   

  	
  Performance Units

  	
   

  
	
  Richard C. Fuisz

  	
   

  	
  1,000,000

  	
   

  
	
  Joe Fuisz

  	
   

  	
  750,000

  	
   

  
	
  Garry Myers

  	
   

  	
  625,000

  	
   

  
	
  Robert Yang

  	
   

  	
  125,000

  	
   

  

 

The grant of Performance Units to a Participant does not
entitle the Participant to voting or any other rights belonging to a member of
the Company.  All rights of a Participant
are set forth herein.  The 2,500,000 Performance
Units granted to the Participants listed above equaled the maximum number of
Performance Units available under the Plan on January 22, 2004 (with such
number subject to adjustment pursuant to the provisions of Section 3.04).  If any Performance Units granted under the
Plan are forfeited or cancelled, such Performance Units may not be granted
again under the Plan.

 

3.03         Vesting
of Performance Units.  A Participant
shall have no right to receive benefit payments on account of any specified
part of his Performance Units except to the extent the Participant is Vested in
his Performance Units.  Based upon the
number of Performance Units granted on January 22, 2004, the Participants hold
the following unadjusted number of Vested Performance Units (with such number
subject to adjustment pursuant to the provisions of Section 3.04 to reflect the
changes made to the Outstanding Unit Amount since January 22, 2004).  The Participants’ Vested Performance Units
remain subject to the forfeiture provisions of Section 4.02.

 

	
  Individual

  	
   

  	
  Performance Units

  	
   

  
	
  Richard C. Fuisz

  	
   

  	
  1,000,000

  	
   

  
	
  Joe Fuisz

  	
   

  	
  750,000

  	
   

  
	
  Garry Myers

  	
   

  	
  625,000

  	
   

  
	
  Robert Yang

  	
   

  	
  62,500

  	
   

  

 

3.04         Dilution
and Other Adjustments.  In the event
of any change in the outstanding ownership interests of the Company by reason
of any issuance of new or additional member interests in the Company, or any
restructuring, recapitalization, merger, consolidation, conversion, spin-off,
reorganization, combination or exchange of interests or other similar change,
the Advisory Board may equitably adjust the Outstanding Unit Amount (including
adjustment to the component thereof which represents the total outstanding
member interests of members of the Company) and/or the number or kind of
Performance Units then subject to the Plan and/or held in Participants’
Performance Unit accounts in order to reflect such changes.  The Advisory Board’s determination as to the
terms of any such adjustment shall be binding and conclusive on all
persons.  Notwithstanding the foregoing, the
Performance Units may be diluted as the result of the authorization and
issuance of additional Performance Units or the

 

4

 

authorization and issuance of additional performance units under the
Additional Performance Units Plan. 
Additionally, in the event of an adjustment under Section 3.2 of the
Acquisition Agreement dated effective as of January 22, 2004 by and between
Kosmos Pharma Limited, the Company, and Monosol LLC, the number of Vested Performance
Units held by each Participant shall be reduced by one-half while the total
Outstanding Unit Amount shall not be changed.

 

ARTICLE IV

BENEFITS

 

4.01         Benefit
Payments Following Change in Control. 
Following a Change in Control, each Participant shall receive payments
in an amount equal to the following:

 

	
  Number of such
  Participant’s

  	
   

  	
   

  	
   

  
	
  Vested Performance
  Units

  	
  X

  	
  (Market Value minus Base Value)  =

  	
  Total Payments

  
	
  Outstanding Unit Amount

  	
   

  	
   

  	
   

  

 

The number of such Participant’s Vested Performance
Units, the Outstanding Unit Amount, and the Market Value shall be determined as
of the date of such Change in Control.

 

Amounts payable under this Section 4.01 shall be paid either in cash
or, at the sole discretion of the Advisory Board, in kind in the same
consideration received by the Company or the members of the Company as a result
of the Change in Control.  Benefits
payable under this Section 4.01 shall be paid to the Participants under this
Section 4.01 within three months following the Change of Control; provided,
however, that if the consideration received by the Company or members of the
Company as a result of  the Change in
Control is deferred and paid over time, then the Participants payments hereunder
shall be deferred and paid as received by the Company or members as the case
may be.  The payment of a Participant’s
entire benefit, if any, under this Section 4.01 shall terminate the Participant’s
interest and status as a Participant under the Plan and result in the
cancellation of his Performance Units. 
For purposes of illustration of these provisions and not by way of
limitation, in connection with a Change in Control resulting from the
occurrence of an initial public offering under the Securities Act of 1933, as
amended, of the business of the Company to the public, the Advisory Board may
elect to pay all or any portion of the amount payable to such Participant under
this Section 4.01 in securities of the newly formed public company.  In any event in which the consideration is
paid in kind to the Participants, the Advisory Board will place a value on the
in kind consideration distributed hereunder for purposes of calculating the
amount paid under this plan for purposes of Article IV of the Company
Agreement.  Notwithstanding anything to
the contrary contained in this Agreement, with respect to the occurrence of a Change
in Control which does not constitute a permissible distribution event under
Code Section 409A(a)(2)(A)(v), all amounts payable under this Section 4.01
shall be paid no later than the later of (i) the date that is 2 1⁄2 months from
the end of the Participant’s tax year in which such Change in Control occurred or
(ii) the date that is 2 1⁄2 months from the end of the Company’s tax year in
which such Change in Control occurred.

 

4.02         Forfeiture
Provisions.  Notwithstanding anything
herein contained to the contrary, all rights to any benefits payable under the
Plan, shall be immediately forfeited, whether or not the Participant holds
Vested Performance Units, if the Participant’s employment or other service-

 

5

 

providing relationship with the Company is terminated for Cause, as
defined for the purposes of this Plan. 
The judgment of the Advisory Board, as expressed by a majority vote,
shall be final as to the whether the Participant has been terminated for Cause.

 

4.03         Withholding;
Payroll Taxes.  To the extent
required by the law in effect at the time payments are made, the Company shall
withhold from payments made hereunder any taxes required to be withheld from a
Participant’s benefit for the federal or any state or local government.

 

ARTICLE V

BENEFICIARY DESIGNATION

 

5.01         Beneficiary
Designation.  Each Participant shall
have the right, at any time, to designate any person or persons as his
Beneficiary or Beneficiaries (both primary as well as contingent) to whom
payment under this Plan shall be paid in the event of his death prior to
complete distribution to the Participant of the benefits due him under the
Plan.  If a Participant fails to
designate a Beneficiary or if all designated Beneficiaries predecease the
Participant or die prior to complete distribution of the Participant’s
benefits, then the Participant’s Beneficiary shall be deemed to be the estate
of the Participant.  The payment to the
Beneficiary or deemed Beneficiary shall completely discharge the Company’s
obligations under the Plan.

 

5.02         Amendments.  Any Beneficiary designation may be changed by
a Participant by the written filing of such change on a form prescribed by the
Advisory Board.  The filing of a new
Beneficiary designation form will, upon receipt by the Advisory Board, cancel
all Beneficiary designations previously filed.

 

ARTICLE VI

AMENDMENT AND TERMINATION

 

6.01         Right
to Amend.  The Company reserves the
right, through its Advisory Board, to amend any provisions under the Plan at
any time; provided, however, that (a) such amendment is in writing, (b) such
amendment is executed by a duly authorized member of the Advisory Board of the
Company, and (c) such amendment does not adversely affect the rights of a
Participant or his Beneficiary.

 

6.02         Termination.  The Company may not terminate this Plan without
the consent of all Participants.

 

6

 

 

ARTICLE VII

CLAIMS PROCEDURE AND DISPUTES

 

7.01         Claim
Filing Procedure.  If a dispute
arises over benefits payable under the Plan, a Claimant shall have the right to
submit a Claim with respect to such benefits. 
Such Claim shall be in writing, signed by the Claimant under oath, and
addressed and delivered to the Advisory Board either personally or by certified
or registered mail, return receipt requested. 
The Claim shall state with particularity:

 

(a)           The
benefit claimed;

(b)           The
provisions of the Plan and the particular provisions of law, if any, upon which
the Claimant relies in support of his Claim; and

(c)           All
facts believed to be relevant in connection with such Claim.

 

7.02         Consideration
of Claim; Rendering of Decision. 
Upon receipt of a Claim hereunder, the Advisory Board shall consider the
merits of the Claim and shall within 90 days from the receipt of the Claim
render a decision on the merits and communicate the same to the Claimant.  In the event the Advisory Board denies the
Claim in whole or in part, the Claimant shall be so notified in writing, which
shall be addressed and delivered to the Claimant personally or by certified or
registered mail, return receipt requested, and shall set forth the following:

 

(a)           The
reason or reasons for rejection of the Claim;

(b)           The
provisions of the Plan and the particular provisions of law, if any, relied
upon in reaching such determination; and

(c)           A
description of any additional information needed from the Claimant in order for
the Claimant to perfect his Claim.

 

The failure of the Advisory Board to render a decision
on the merits of a Claim shall be deemed to be a denial of such Claim and
notice of such denial shall be deemed to have been given to the Claimant on the
ninetieth (90th) day from receipt by the Advisory Board of the Claim.

 

7.03         Limitation
on Claims Procedure.  Any Claim under
this Claims procedure must be submitted within six months from the earlier of
(1) the date on which the Claimant learned of facts sufficient to enable him to
formulate such Claim, or (2) the date on which the Claimant should reasonably
have been expected to learn the facts sufficient to enable him to formulate
such Claim.  For this purpose, the first
date on which any document that is either given to or made available to a
Participant or Beneficiary (in pay status), and which discloses facts
sufficient to enable a reasonable person to formulate a Claim hereunder, shall
be conclusively deemed to be the date on which the Claimant should reasonably
have been expected to learn the facts sufficient to enable him to formulate
such a Claim.  Claims submitted after
such period shall be deemed to have been waived by the Claimant and shall
thereafter be wholly unenforceable.

 

7.04         Dispute
over Benefits.  If a dispute arises
as to the amount or proper recipient of any payment, the Advisory Board, in its
sole discretion, may withhold or cause to be withheld

 

7

 

such payment until the dispute shall have been settled by the parties
concerned or shall have been determined by an arbitration proceeding.  In addition, if a dispute continues to exist
after a Claim has been filed and a decision rendered by the Advisory Board
under the Claims procedure set forth above, or in the event of any dispute or
controversy concerning the construction, interpretation, performance or breach
of the Plan arising between a Participant, the Company or the Advisory Board,
the same shall be submitted to arbitration under the appropriate rules of the
American Arbitration Association.  Any
arbitration shall be conducted in Fort Worth, Texas, unless mutually agreed
otherwise by the parties.  All
administrative fees connected with initiating a demand for arbitration shall be
split between and advanced by the parties to the arbitration; subject, however,
to final apportionment by the arbitrator in his award.  The parties agree that the arbitrator’s award
shall be binding and may be enforced in any court having jurisdiction thereof
by filing a petition for enforcement of such award.

 

ARTICLE VIII

MISCELLANEOUS

 

8.01         Headings
and Gender.  The headings of the Plan
have been inserted for convenience of reference only and are to be ignored in
any construction of the provisions hereof. 
Whenever a personal pronoun is used in the masculine gender, it shall be
deemed to include the feminine also, unless the context indicates the contrary.

 

8.02         No
Right to Employment or Retention. 
Nothing herein contained shall be construed as giving any Participant
the right to be retained in the service of the Company.

 

8.03         Action
by Officers.  Whenever under the
terms of this Plan the Company is permitted or required to take some action,
such action may be taken by any duly authorized member of the Advisory Board or
officer of the Company.

 

8.04         Assignment
of Benefits.  Except as provided in
this Section 8.04, no interest in this Plan shall be subject to assignment,
alienation, transfer or anticipation, either by voluntary or involuntary act of
any Participant or Beneficiary or by operation of law, nor shall payment or
right of interest be subject to the demands or claims of any creditor of such
person, nor be liable in any way for such person’s debts, obligations or
liabilities.

 

The Company shall not merge or consolidate with any other entity or
otherwise reorganize unless and until such succeeding entity agrees to assume
and discharge the obligations of the Company under the Plan.  Upon such assumption, the term “Company” as
used in this Plan shall be deemed to refer to such successor entity.

 

8.05         Applicable
Law; Validity.  The validity of the
Plan or any of its provisions shall be determined under and construed according
to the laws of the State of Delaware.  If
any provision of the Plan shall be held illegal or invalid for any reason, such
determination shall not affect the remaining provisions of the Plan and it
shall be construed as if said illegal or invalid provision had never been
included.

 

8

 

8.06         Expenses.  The administration costs incurred with
respect to the Plan shall be paid by the Company as an ordinary and necessary
business expense incurred in the operation of the Company’s business.

 

8.07         Plan
Funding.  Benefits under the Plan are
payable solely by the Company.  The
Company may, in its sole discretion, determine to set aside funds in a trust or
other arrangement to satisfy its obligations hereunder; provided, the trust or
other arrangement shall be unfunded for purposes of the Code, such trust or
other arrangement shall not be structured in a manner which would cause the
assets to be deemed to have been paid to the Participants under Code Section
409A(b), and no Participant or Beneficiary shall be considered to have an
interest in any such trust or other arrangement, or the assets held pursuant
thereto, except as may be specifically provided for therein.  Participants shall be regarded as general
creditors of the Company with respect to any rights derived by Participants from
the existence of the Plan.

 

[REMAINDER OF THIS PAGE
INTENTIONALLY LEFT BLANK]

 

9

 

IN WITNESS WHEREOF, the
Company has caused this Amended and Restated Plan to be executed by its duly
authorized officers to be effective as of September 18, 2006.

 

	
   

  	
  MONOSOL RX, LLC

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
  MONOSOL RX GENPAR, a
  Texas limited partnership

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
  BRATTON CAPITAL, INC.,
  its general partner

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
  By:

  	
  /s/ John Cochran

  
	
   

  	
   

  	
  Name:

  	
  John Cochran

  
	
   

  	
   

  	
  Title:

  	
  Vice President

  
					

 

10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00123-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00123-of-00352.parquet"}]]